Cefoperazone versus ceftazidime monotherapy of nosocomial pneumonia.
Cefoperazone and ceftazidime monotherapy were compared in a randomized, prospective evaluation of patients with nosocomial pneumonia. These antibiotics were equally effective, with an overall successful treatment rate of 45 of 62 (73 percent) for cefoperazone-treated patients and 50 of 63 (79 percent) for ceftazidime-treated patients (p = 0.41). There was no difference in the incidence of side effects (including hypoprothrombinemia), superinfections, or colonization of the oropharynx with yeast, enterococcus, Staphylococcus aureus, or resistant gram-negative bacilli. When antibiotic administration, and laboratory costs are considered, cefoperazone is less expensive than ceftazidime. Both cefoperazone and ceftazidime are effective therapy for nosocomial pneumonia.
D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D002438:Cefoperazone / Q000009:adverse effects / Q000627:therapeutic use*; D002442:Ceftazidime / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D003428:Cross Infection / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy* / Q000191:economics; D011446:Prospective Studies; D011897:Random Allocation; D013183:Sputum / Q000382:microbiology
D002438:Cefoperazone; D002442:Ceftazidime